Abstract: A method for determining or diagnosing the presence or absence, or the risk of development, or the therapy control of autoimmune hepatitis in a subject is provided. In a method, the presence or absence of antibodies against the huntingtin interacting protein 1 related protein (HIP1R) or against immunoreactive peptides derived therefrom are analyzed, the presence of said antibodies is indicative for the presence, or the risk of development or for therapy control of autoimmune hepatitis of the subject. The use of the HIP1R or an immunoreactive peptide derived therefrom in the diagnosis, the risk assessment or therapy control of hepatitis diseases by determining the presence of antibodies against said HIP1R or immunoreactive peptide derived therefrom, may be helpful for differential diagnosis of autoimmune hepatitis.

Abstract: The present invention relates generally to a method for determining or diagnosing the presence or absence, or the risk of development, or the therapy control of autoimmune hepatitis in a subject, in particular, in mammals. In addition, the present invention relates to test kits for use in the diagnosis or the determination of the presence or absence, or the risk of development or the therapy control of autoimmune hepatitis in a subject. In particular, the present invention relates to a method wherein the presence or absence of antibodies against the huntingtin interacting protein 1 related protein (HIP1 R) or against immunoreactive peptides derived therefrom are analyzed, the presence of said antibodies is indicative for the presence, or the risk of development or for therapy control of autoimmune hepatitis of said subject.